TRC003

TRC003 is an investigational radiopharmaceutical developed by Tongrui Biopharmaceutical (Chengdu) Co., Ltd. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of a small-molecule ligand that specifically targets Prostate-Specific Membrane Antigen (PSMA), which is highly overexpressed on the surface of prostate cancer cells, conjugated to the alpha-emitting radioisotope Actinium-225 ($^{225}$Ac). Upon binding to PSMA and subsequent internalization, the drug delivers high-energy alpha particles directly to the tumor cells. These alpha particles have a high linear energy transfer (LET) and a very short range in tissue, causing lethal DNA double-strand breaks while minimizing damage to surrounding healthy tissues. TRC003 is currently being evaluated in early-phase clinical trials in China as a next-generation targeted alpha therapy.

Other names

225Ac-TRC003Actinium-225 labeled PSMA ligandActinium225 labeled PSMA ligandActinium 225 labeled PSMA ligand